Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors
Hana Kubová1, Zdeňka Bendová2,3, Simona Moravcová2,3
1Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic.
Insights
Neonatal exposure to clonazepam alters GABAergic receptor expression and binding in developing rats, potentially leading to long-term behavioral deficits. These changes impact key brain regions involved in emotion and cognition.
Area of Science:
- Neuroscience
- Pharmacology
- Developmental Biology
Background:
- Benzodiazepines (BZDs) are widely prescribed but can cause behavioral deficits in neonates.
- Mechanisms of BZD-induced neurodevelopmental effects remain unclear.
Purpose of the Study:
- To investigate the short- and long-term effects of neonatal clonazepam (CZP) exposure on GABAergic receptors in rats.
- To determine the impact on GABAA and GABAB receptor subunit expression and binding.
Main Methods:
- Neonatal rats (7-11 days old) received daily clonazepam (1 mg/kg).
- RT-PCR and quantitative autoradiography assessed GABA receptor subunit expression and binding.
- Analyses were conducted 48 hours, 1 week, and 2 months post-treatment.
Main Results:
- Clonazepam altered GABAA receptor subunit expression (e.g., α2, δ, α4) in hippocampus and cortex.
- GABAA receptor binding increased acutely, while benzodiazepine binding decreased long-term in emotion/cognition-related areas.
- GABAB receptor binding varied by brain region and time post-treatment.
Conclusions:
- Neonatal clonazepam exposure induces lasting changes in GABAergic receptor systems.
- These alterations in synaptic function may underlie observed behavioral impairments.
- Findings highlight critical developmental periods for BZD neurotoxicity.
Abstract:
Benzodiazepines (BZDs) are widely used in patients of all ages. Unlike adults, neonatal animals treated with BZDs exhibit a variety of behavioral deficits later in life; however, the mechanisms underlying these deficits are poorly understood. This study aims to examine whether administration of clonazepam (CZP; 1 mg/kg/day) in 7-11-day-old rats affects Gama aminobutyric acid (GABA)ergic receptors in both the short and long terms. Using RT-PCR and quantitative autoradiography, we examined the expression of the selected GABAA receptor subunits (α1, α2, α4, γ2, and δ) and the GABAB B2 subunit, and GABAA, benzodiazepine, and GABAB receptor binding 48 h, 1 week, and 2 months after treatment discontinuation. Within one week after CZP cessation, the expression of the α2 subunit was upregulated, whereas that of the δ subunit was downregulated in both the hippocampus and cortex. In the hippocampus, the α4 subunit was downregulated after the 2-month interval. Changes in receptor binding were highly dependent on the receptor type, the interval after treatment cessation, and the brain structure. GABAA receptor binding was increased in almost all of the brain structures after the 48-h interval. BZD-binding was decreased in many brain structures involved in the neuronal networks associated with emotional behavior, anxiety, and cognitive functions after the 2-month interval. Binding of the GABAB receptors changed depending on the interval and brain structure. Overall, the described changes may affect both synaptic development and functioning and may potentially cause behavioral impairment.
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Desensitization and Tachyphylaxis
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...


